Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly’s expectations for sales ... its diabetes and obesity drugs Mounjaro and Zepbound. This is another notable stumble for the company after its third-quarter earnings report disappointed.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest ... increase employers faced in 2024 and in 2023, comes before any “cost savings strategies” are implemented ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Eli Lilly announced preliminary fourth ... for diabetes drug Mounjaro and obesity drug Zepbound. Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

It fell last week after the company ... so have expectations. Eli Lilly's stock is off to a tough start in 2025, and it could continue that way unless Mounjaro's and Zepbound's performances ...

Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss drugs like Zepbound and Novo Nordisk's Ozempic ...